Table 1 Descriptive of subjects’ characteristics in the study according to disease and treatment status. Continuous variables are described by medians, minimum and maximum values; categorical variables are summarized using absolute frequencies and percentages. p-values are derived from a Mann–Whitney (continuous) or a Fisher's test (categorical variables).
All n = 76 | Control n = 37 (48.7%) | Not-treated n = 10 (13.2%) | First-Line n = 10 (13.2%) | Second-Line n = 10 (13.2%) | Third-Line n = 9 (11.8%) | p-value | ||
|---|---|---|---|---|---|---|---|---|
Sex | Female | 65 (85.5%) | 30 (81.1%) | 10 (100.0%) | 10 (100.0%) | 8 (80.0%) | 7 (77.8%) | 0.3315 |
Male | 11 (14.5%) | 7 (18.9%) | 0 (0.0%) | 0 (0.0%) | 2 (20.0%) | 2 (22.2%) | ||
Age at sample extraction | 46.0 (20.0, 82.8) | 38.0 (20.0, 67.0) | 56.8 (45.2, 82.8) | 50.1 (34.6, 75.1) | 51.5 (45.0, 81.8) | 45.4 (34.8, 70.0) | < 0.0001 | |
Time from vaccination to sample extraction (months) | 3.4 (2.3, 5.5) | 3.3 (2.6, 4.3) | 3.3 (2.3, 4.3) | 3.4 (3.3, 4.1) | 3.9 (3.3, 4.4) | 3.5 (3.1, 5.5) | 0.0064 | |
Vaccine type | Moderna | 44 (57.9%) | 17 (45.9%) | 5 (50.0%) | 7 (70.0%) | 6 (60.0%) | 9 (100.0%) | 0.0329 |
Pfizer | 32 (42.1%) | 20 (54.1%) | 5 (50.0%) | 3 (30.0%) | 4 (40.0%) | 0 (0.0%) | ||
Time of disease evolution (years) | 14.3 (2.3, 39.4) | 17.8 (7.2, 36.3) | 11.7 (6.3, 36.3) | 13.8 (2.3, 36.3) | 16.2 (4.3, 39.4) | 0.5892 | ||
Any Concomitant Treatment | No | 20 (51.3%) | 9 (90.0%) | 7 (70.0%) | 3 (30.0%) | 1 (11.1%) | 0.0016 | |
Yes | 19 (48.7%) | 1 (10.0%) | 3 (30.0%) | 7 (70.0%) | 8 (88.9%) | |||
Concomitant Treatment with Clucocorticoids | No | 30 (76.9%) | 9 (90.0%) | 7 (70.0%) | 7 (70.0%) | 7 (77.8%) | 0.7575 | |
Yes | 9 (23.1%) | 1 (10.0%) | 3 (30.0%) | 3 (30.0%) | 2 (22.2%) | |||
SLEDAI 2 years average | SLEDAI < 4 | 36 (92.3%) | 9 (90.0%) | 10 (100.0%) | 9 (90.0%) | 8 (88.9%) | ||
SLEDAI [4, 6) | 3 (7.7%) | 1 (10.0%) | 0 (0.0%) | 1(10.0%) | 1 (11.1%) | |||
SLEDAI nearest to vaccination | SLEDAI < 4 | 34 (87.2%) | 8 (80.0%) | 9 (90.0%) | 9 (90.0%) | 8 (88.9%) | ||
SLEDAI [4, 6) | 3 (7.7%) | 1 (10.0%) | 0 (0.0%) | 1 (10.0%) | 1 (11.1%) | |||
SLEDAI 6 + | 2 (5.1%) | 1 (10.0%) | 1 (10.0%) | 0 (0.0%) | 0 (0.0%) | |||
